GLAUKOS Corp (GKOS) stock
Close on Nov 11, 2026Market cap $14.63BP/E –Yield –
GLAUKOS Corp grew revenue 46.9% to $690.33M over the twelve months to Sep 30, 2026. Free cash flow was $36.02M. At the latest close the market valued the company at $14.63B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $14.63B
- P/E ratio
- –
- Price to sales
- 21.19
- Price to book
- 20.40
- Dividend yield
- –
- Free cash flow yield
- 0.25%
Fundamentals
- Revenue
- $690.33M
- Net income
- -$169.80M
- EPS, diluted
- -$2.94
- Free cash flow
- $36.02M
- Book value per share
- $11.72
- Diluted shares
- 61M
Trading
- Next earnings
- Feb 16, 2027 (estimated, after the close)
- Previous close
- $236.19
- Open
- $237.54
- Day's range
- $237.54 – $248.27
- Volume
- 915,622
- Average volume (20 days)
- 1,922,850
- Index membership
- S&P SmallCap 600 (since May 2020), Russell 2000, Russell 3000
- Beta (5 years)
- 1.02
- 52-week range
- $87.32 – $255.19
- RSI (14 days)
- 69.6
- Volatility (1 year)
- 61.3%
- Relative volume
- 0.85×
- WACC
- 10.0%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GKOS | S&P 500 | Difference | GKOS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +49.2% | -2.4% | +51.6 pts | ||
| 3 months | +35.8% | -1.2% | +37.0 pts | ||
| Year to date | +118.9% | +12.3% | +106.6 pts | ||
| 1 year | +175.0% | +12.4% | +162.5 pts | ||
| 3 years | +308.3% | +78.8% | +229.4 pts | +59.8% | +21.4% |
| 5 years | +381.7% | +75.2% | +306.5 pts | +36.9% | +11.9% |
| 10 years | +626.7% | +311.1% | +315.6 pts | +21.9% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Glaukos filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Results
- Results
About Glaukos
Surgical & Medical Instruments & Apparatus
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio and pipeline include micro-invasive glaucoma surgery devices such as iStent, iStent inject W, and iStent infinite, sustained-release pharmaceuticals including iDose TR, and corneal health treatments such as Photrexa and Epioxa. The company operates in key therapeutic areas centered on glaucoma and corneal health, serving ophthalmic surgeons and specialized eye care professionals.
Company profile, executives and historyGlaukos stock: common questions
What is Glaukos's stock price?
GKOS closed at $247.16 on Nov 11, 2026, up 4.64% on the day. Over the past 52 weeks it traded between $87.32 and $255.19.
What is Glaukos's market cap?
Glaukos was worth $14.63B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GKOS's P/E ratio?
Glaukos lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.94), so it has no meaningful P/E ratio.
How much revenue does Glaukos make?
Glaukos reported revenue of $690.33M for the twelve months to Sep 30, 2026, up 46.9% from a year earlier.
Does Glaukos pay a dividend?
No. Glaukos has not paid a cash dividend over the last twelve months.
When does Glaukos report earnings next?
Glaukos is expected to report Q4 FY2026 results on Feb 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GKOS stock performed over the past year?
Including dividends, GKOS returned +175.0% over the past year, against +12.4% for the S&P 500.
How many GKOS shares are sold short?
4M shares were sold short at the latest FINRA report, 7.99% of the float, or 2.9 days of average trading volume.
Who are Glaukos's competitors?
Companies most similar to Glaukos by business, industry and size include OFIX, SGHT, NVCR, BVS, ATEC.
See a number that looks wrong?